Physician profile
Stephanie Vlahovic
NPI 1912454877
$1,814.69
in general payments reported to CMS, 2019-2025
21 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.47 · 2022: $727 · 2023: $459 · 2024: $360 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $269.13 | 2022-2025 | |
| Glaxosmithkline, LLC. | $247.48 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $244.52 | 2022-2025 | |
| Novo Nordisk INC | $212.28 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $125.18 | 2022-2024 | Mounjaro |
| Amgen INC. | $106.90 | 2022-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $83.21 | 2022-2024 | |
| Exact Sciences Corporation | $75.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $62.37 | 2024-2025 | Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $54.05 | 2022 | |
| Vanda Pharmaceuticals INC. | $41.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.07 | 2024-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $33.75 | 2022-2023 | Eliquis |
| Almatica Pharma LLC | $33.68 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.35 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $23.91 | 2024 | Voquezna |
| Abbott Laboratories | $23.12 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $21.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Vlahovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.